Spots Global Cancer Trial Database for neuroendocrine differentiation
Every month we try and update this database with for neuroendocrine differentiation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation | NCT06414915 | NSCLC | Surufatinib Tislelizumab | 18 Years - 75 Years | National Cancer Center, China | |
| Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy | NCT03017794 | Prostate Cancer | 18 Years - | Mayo Clinic |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
